Alzheimer's disease: A need for personalized therapeutic approaches

Frenkel, Dan

doi:10.1002/ddr.21652

Cited by 6 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, atherosclerosis or cardiac dysfunction may appear in one AD patient but be absent in another. As Frenkel (2020) noted, there is the potential of an “arsenal of drugs that can be used to personalize medicine for each patient in the spectrum of diseases associated with AD” [ 118 ]. This approach, however, still faces many challenges, such as determining which “cocktail” of drugs to use and how drugs interact with one another, but nanotechnological constructs offer one possible route to personalize therapeutic protocols.…”

Section: Discussionmentioning

confidence: 99%

Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies

2023

View full text Add to dashboard Cite

Nanomaterials play an increasingly important role in current medicinal practice. As one of the most significant causes of human mortality, and one that is increasing year by year, Alzheimer’s disease (AD) has been the subject of a very great body of research and is an area in which nanomedicinal approaches show great promise. Dendrimers are a class of multivalent nanomaterials which can accommodate a wide range of modifications that enable them to be used as drug delivery systems. By means of suitable design, they can incorporate multiple functionalities to enable transport across the blood–brain barrier and subsequently target the diseased areas of the brain. In addition, a number of dendrimers by themselves often display therapeutic potential for AD. In this review, the various hypotheses relating to the development of AD and the proposed therapeutic interventions involving dendrimer–base systems are outlined. Special attention is focused on more recent results and on the importance of aspects such as oxidative stress, neuroinflammation and mitochondrial dysfunction in approaches to the design of new treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies

2023

View full text Add to dashboard Cite

show abstract

“…However, AD is not solely attributed to a single factor like AChE inhibition; instead, it is a multifactorial condition. Factors like oxidative stress, neuroinflammation, neurotransmitter imbalance, and mitochondrial and synaptic dysfunction are also key contributors to cognitive decline [ 8 , 9 ]. Consequently, the most effective therapy for AD should be able to influence the disease via multiple pathways rather than targeting a single dysregulated mechanism.…”

Section: Introductionmentioning

confidence: 99%

Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer’s Disease Treatment

Stanciu,

Ababei,

Solcan

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Despite decades of rigorous research and numerous clinical trials, Alzheimer’s disease (AD) stands as a notable healthcare challenge of this century, with effective therapeutic solutions remaining elusive. Recently, the endocannabinoid system (ECS) has emerged as an essential therapeutic target due to its regulatory role in different physiological processes, such as neuroprotection, modulation of inflammation, and synaptic plasticity. This aligns with previous research showing that cannabinoid receptor ligands have the potential to trigger the functional structure of neuronal and brain networks, potentially impacting memory processing. Therefore, our study aims to assess the effects of prolonged, intermittent exposure (over 90 days) to JWH-133 (0.2 mg/kg) and an EU-GMP certified Cannabis sativa L. (Cannabixir® Medium Flos, 2.5 mg/kg) on recognition memory, as well as their influence on brain metabolism and modulation of the expanded endocannabinoid system in APP/PS1 mice. Chronic therapy with cannabinoid receptor ligands resulted in reduced anxiety-like behavior and partially reversed the cognitive deficits. Additionally, a reduction was observed in both the number and size of Aβ plaque deposits, along with decreased cerebral glucose metabolism, as well as a decline in the expression of mTOR and CB2 receptors. Furthermore, the study revealed enlarged astrocytes and enhanced expression of M1 mAChR in mice subjected to cannabinoid treatment. Our findings highlight the pivotal involvement of the extended endocannabinoid system in cognitive decline and pathological aspects associated with AD, presenting essential preclinical evidence to support the continued exploration and assessment of cannabinoid receptor ligands for AD treatment.

show abstract

“…At present, there are no effective treatments. While much emphasis has been given to the amyloid and tau proteins, multiple factors are involved in the causation of AD, including mitochondrial dysfunction, oxidative stress, unbalanced iron metabolism, and neuroinflammation [ 2 , 3 ]. Consequently, treating the end result of the disease, such as focusing on amyloid beta (Aβ) peptides or tau phosphorylation, has not yielded satisfactory results.…”

Section: Introductionmentioning

confidence: 99%

An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer’s Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model

Nitzan

Ellenbogen

Bentulila

et al. 2022

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia, but there is still no available treatment. Δ9-tetrahydrocannabinol (THC) is emerging as a promising therapeutic agent. Using THC in conventional high doses may have deleterious effects. Therefore, we propose to use an ultra-low dose of THC (ULD-THC). We previously published that a single injection of ULD-THC ameliorated cognitive functioning in several models of brain injuries as well as in naturally aging mice. Here, 5xFAD AD model mice received a single treatment of ULD-THC (0.002 mg/kg) after disease onset and were examined in two separate experiments for cognitive functions, neurotropic, and inflammatory factors in the hippocampus. We show that a single injection of ULD-THC alleviated cognitive impairments in 6- and 12-month-old 5xFAD mice. On the biochemical level, our results indicate an imbalance between the truncated TrkB receptor isoform and the full receptor, with AD mice showing a greater tendency to express the truncated receptor, and ULD-THC improved this imbalance. We also investigated the expression of three AD-related inflammatory markers and found an ameliorating effect of ULD-THC. The current research demonstrates for the first time the beneficial effects of a single ultra-low dose of THC in a mouse model of AD after disease onset.

show abstract

Alzheimer's disease: A need for personalized therapeutic approaches

Cited by 6 publications

References 33 publications

Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies

Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies

Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer’s Disease Treatment

An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer’s Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model

Contact Info

Product

Resources

About